Zobrazeno 1 - 10
of 12
pro vyhledávání: '"J. Gomez Puerta"'
Autor:
Raimon Sanmartí, Beatriz Frade-Sosa, J. Ramirez, José Inciarte-Mundo, Raul Castellanos-Moreira, Juan D. Cañete, Virginia Ruiz, J. Gomez Puerta, Rosa Morlà
Publikováno v:
Annals of the Rheumatic Diseases. 79:596.1-596
Background:Patients and Rheumatologist often differ in their perception of RA disease activity. Remission or low disease activity should be the treatment target in RA, patients should be included in treatment decisions.Objectives:To identify factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db999cdecc4182d642c07b6f8c8d1077
https://doi.org/10.1136/annrheumdis-2020-eular.5516
https://doi.org/10.1136/annrheumdis-2020-eular.5516
Autor:
María J. Gómara, Ivette Casafont-Solé, José Federico Ramírez, Raimon Sanmartí, J. Gomez Puerta, K. Cajiao, Isabel Haro, G. Jimenez, Raul Castellanos-Moreira, Sebastian C. Rodriguez-García, Juan D. Cañete, S. Holgado Pérez, Virginia Ruiz
Publikováno v:
Annals of the Rheumatic Diseases. 79:944.2-945
Background:Interstitial lung disease (ILD) is associated with a significant increase in morbidity and mortality in patients with rheumatoid arthritis (RA). Therefore, an early diagnosis is fundamental. Anti-carbamylated proteins (Anti-CarP) have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae55598ef318271a0f35d8e99a68fe50
https://doi.org/10.1136/annrheumdis-2020-eular.1993
https://doi.org/10.1136/annrheumdis-2020-eular.1993
Autor:
Andrea Cuervo, J. Gomez Puerta, Raimon Sanmartí, S.D.L.C. Rodriguez García, O. Camacho, Juan D. Cañete, J. Ramirez, Raul Castellanos-Moreira, M.V. Hernandez-Miguel, Virginia Ruiz-Esquide
Publikováno v:
Rheumatoid arthritis – biological DMARDs.
Background Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) in patients who failed to respond to tumour necrosis factor inhibitors (TNFi). Due to its effect on induction of B cell deplet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::459ad177fcf5dd492466300caf3434f8
https://doi.org/10.1136/annrheumdis-2018-eular.3634
https://doi.org/10.1136/annrheumdis-2018-eular.3634
Autor:
Juan D. Cañete, O. Camacho, J. Gomez Puerta, M.V. Hernandez-Miguel, J. Ramirez, Raimon Sanmartí, Raul Castellanos-Moreira, Andrea Cuervo, S.D.L.C. Rodriguez García, Virginia Ruiz-Esquide
Publikováno v:
Rheumatoid arthritis – biological DMARDs.
Background The standard dose of rituximab (RTX) in rheumatoid arthritis (RA) is two intravenous (iv) 1 g infusions, separated by two weeks. Recently, the efficacy of a low-dose of RTX for retreatment in RA patients has been reported.1 Objectives Our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43fe6ff9afc199dc808fa460c0458aa8
https://doi.org/10.1136/annrheumdis-2018-eular.4008
https://doi.org/10.1136/annrheumdis-2018-eular.4008
AB0332 Comorbidities prevalence and charlson index in a cohort of patients with rheumatoid arthritis
Autor:
Raimon Sanmartí, Ana Belén Azuaga-Piñango, C. Gonzalez-Delaurens, O. Camacho, J. Gomez Puerta, Mirtha Hernández, Virginia Ruiz-Esquide, Sebastian C. Rodriguez-García, N. Sapena, Beatriz Frade-Sosa, Andrea Cuervo, S. Mandelikova, Raul Castellanos-Moreira, A. Diaz-Castillo, Juan D. Cañete, J. Ramirez
Publikováno v:
Rheumatoid arthritis – comorbidity and clinical aspects.
Background The Charlson comorbidity index (CCI) is a prognostic scale, which gives a numerical value that indicates the burden of comorbidities in a patient. This index is obtained from the sum of 19 medical conditions that have been related to morta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2641136d34b804eccf1a08e25436239d
https://doi.org/10.1136/annrheumdis-2018-eular.3216
https://doi.org/10.1136/annrheumdis-2018-eular.3216
192 Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus
Autor:
Gloria M Vazquez, Francisco Caeiro, Enrique R. Soriano, Leonor A Barile-Fabris, I Garcia De La Torre, B A Pons-Estel, Loreto Massardo, M I Segami, Cristina Drenkard, Daniel Wojdyla, Guillermo J. Pons-Estel, Eloisa Silva Dutra de Oliveira Bonfa, Graciela S. Alarcón, Manuel F. Ugarte-Gil, Rosa Serrano, Virginia Pascual-Ramos, Marlene Guibert-Toledano, J Gomez Puerta, M A García, Guillermo A. Berbotto
Publikováno v:
Poster Session.
Background and aims Antimalarials (AMs) have been shown to exert a reduced risk of damage accrual in North American and European SLE patients. We are presenting data from Latin American patients. Methods Patients with a recent SLE diagnosis (≤2 yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7233045b1ee75eec8fc4203d03644cea
https://doi.org/10.1136/lupus-2017-000215.192
https://doi.org/10.1136/lupus-2017-000215.192
Autor:
Y Shoenfeld, J. Gomez Puerta, Ronald A. Asherson, Gerard Espinosa, Silvia Bucciarelli, Wolfgang Miesbach, Ricard Cervera
Publikováno v:
Clinical Rheumatology. 26:2109-2114
The catastrophic anti-phospholipid syndrome (CAPS) differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. In this study, the occurrence of malignancies in patients with CAPS was evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abea976cad80164edbc917299a78767
https://doi.org/10.1007/s10067-007-0634-x
https://doi.org/10.1007/s10067-007-0634-x
Autor:
J. Gomez Puerta, Ronald A. Asherson, G. Espinoza, Silvia Bucciarelli, Wolfgang Miesbach, Ricard Cervera, Josep Font, Y Shoenfeld
Publikováno v:
Autoimmunity reviews. 6(2)
The catastrophic antiphospholipid syndrome is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels. It has been reported as frequently occurring in patients with underlying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7aef89be4eff6678c4985e47279a916
https://pubmed.ncbi.nlm.nih.gov/17138251
https://pubmed.ncbi.nlm.nih.gov/17138251
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.